Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

被引：12
|
作者：
Su, Po-Lan [1 ]
Lin, Chien-Yu [1 ]
Chen, Yi-Lin [2 ]
Chen, Wan-Li [2 ]
Lin, Chien-Chung [1 ,3 ,4 ]
Su, Wu-Chou [3 ,5 ,6 ,7 ]
机构：
[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Clin Med, Coll Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, Tainan, Taiwan
[6] Natl Cheng Kung Univ, Ctr Appl Nanomed, Tainan, Taiwan
[7] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, 138 Shengli Rd, Tainan 704, Taiwan
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 08期
关键词：
BRAF K601E mutation; Adenocarcinoma; Dab-rafenib; Trametinib; Case report; TARGETED THERAPY; CANCER;
D O I：
10.1016/j.jtocrr.2021.100202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Nonesmall-cell Lung Cancer
    Pervere, Leah M.
    Rakshit, Sagar
    Schrock, Alexa B.
    Miller, Vincent A.
    Ali, Siraj M.
    Velcheti, Vamsidhar
    CLINICAL LUNG CANCER, 2017, 18 (03) : E211 - E213
  • [22] Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report
    Inoue, Takako
    Kunimasa, Kei
    Tamiya, Motohiro
    Kawamura, Takahisa
    Minami, Toshiyuki
    Nishino, Kazumi
    THORACIC CANCER, 2024, 15 (11) : 929 - 933
  • [23] Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a US Commercial Payer Perspective
    Stellato, Daniel
    Gerbasi, Margaret E.
    Ndife, Briana
    Ghate, Sameer R.
    Moynahan, Aaron
    Mishra, Dinesh
    Gunda, Praveen
    Koruth, Roy
    Delea, Thomas E.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1227 - +
  • [24] Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
    Gerbasi, Margaret E.
    Stellato, Daniel
    Ghate, Sameer R.
    Ndife, Briana
    Moynahan, Aaron
    Mishra, Dinesh
    Gunda, Praveen
    Koruth, Roy
    Delea, Thomas E.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) : 1243 - 1252
  • [25] Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report
    Ninomaru, Taira
    Okada, Hideaki
    Fujishima, Mika
    Irie, Kei
    Fukushima, Shoji
    Hata, Akito
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [26] Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
    Chou, Yun-Tse
    Lin, Chien-Chung
    Lee, Chung-Ta
    Pavlick, Dean C.
    Su, Po-Lan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
    Wang, Wei
    Smith, Jessica Louise
    Carlino, Matteo Salvatore
    Burmeister, Bryan
    Pinkham, Mark Blayne
    Fogarty, Gerald Blaise
    Christie, David Robert Harry
    Estall, Vanessa
    Shackleton, Mark
    Clements, Arthur
    Wolfe, Rory
    Le Thi Phuong Thao
    Paton, Elizabeth Jane
    Steel, Victoria
    Williams, Narelle Catherine
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
  • [28] Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
    Janet Pan
    Clinical Drug Investigation, 2019, 39 : 1003 - 1007
  • [29] Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer
    Sharp, John A.
    Jones, Daniel
    Rotow, Julia K.
    Fidias, Panos M.
    Bertino, Erin
    Owen, Dwight H.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (03):
  • [30] Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression
    Zhang, Huimin
    Cong, Xiaofeng
    Yin, Jiaxin
    Chen, Chen
    Liu, Ziling
    FRONTIERS IN ONCOLOGY, 2024, 14
12345